SCHEMBL1243323

SCHEMBL1243323

CCC(NC(=O)c1cn(CC)c2cc(NC3CCCCC3)c(F)cc2c1=O)C(=O)O

nearest known ligand 0.75

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.75
KMT2A Q03164 6/20 0.75
GAA P10253 4/20 0.75
FOXO1 Q12778 1/20 0.52
KDM4E B2RXH2 6/20 0.50
ALDH1A1 P00352 5/20 0.47
LMNA P02545 3/20 0.47
RAD52 P43351 1/20 0.45
HPGD P15428 2/20 0.44
POLB P06746 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
HSD17B10 Q99714 2/20 0.43
DRD3 P35462 1/20 0.43
BRD4 O60885 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
CYP2J2 P51589 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1243135 0.93 MEN1 (0.65) MEN1KMT2AGAAFOXO1KDM4E
SCHEMBL1243614 0.90 MEN1 (0.60) MEN1KMT2AGAAFOXO1KDM4E
SCHEMBL1243462 0.90 MEN1 (0.60) MEN1KMT2AGAAFOXO1KDM4E
SCHEMBL1242841 0.88 MEN1 (0.58) MEN1KMT2AGAAFOXO1KDM4E
SCHEMBL4111281 0.86 MEN1 (1.00) MEN1KMT2AGAAFOXO1KDM4E
SCHEMBL1243831 0.86 MEN1 (0.85) MEN1KMT2AGAAFOXO1KDM4E
SCHEMBL1243866 0.85 KMT2A (0.81) MEN1KMT2AGAAFOXO1KDM4E
SCHEMBL1242762 0.85 MEN1 (0.55) MEN1KMT2AGAAFOXO1KDM4E
SCHEMBL4110428 0.84 MEN1 (0.79) MEN1KMT2AGAAFOXO1KDM4E
SCHEMBL261670 0.84 MEN1 (0.61) MEN1KMT2AGAAFOXO1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879878-B2 such as {2-[({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino]ethyl}phosphonic acid, used as platelet aggregation inhibitor and purinergic receptor (P2Y12) inhibitors; therapy for circulatory diseases involving thrombosis via platelet aggregation ASTELLAS PHARMA INC. (JP) 2011-02-01 US disclosed